Suppr超能文献

采用幼稚 T 细胞耗竭预防慢性移植物抗宿主病。

Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.

机构信息

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Department of Pediatrics, University of Washington, Seattle, WA.

出版信息

J Clin Oncol. 2022 Apr 10;40(11):1174-1185. doi: 10.1200/JCO.21.01755. Epub 2022 Jan 10.

Abstract

PURPOSE

Graft-versus-host disease (GVHD) causes morbidity and mortality following allogeneic hematopoietic cell transplantation. Naive T cells (T) cause severe GVHD in murine models. We evaluated chronic GVHD (cGVHD) and other outcomes in three phase II clinical trials of T-depletion of peripheral blood stem-cell (PBSC) grafts.

METHODS

One hundred thirty-eight patients with acute leukemia received T-depleted PBSC from HLA-matched related or unrelated donors following conditioning with high- or intermediate-dose total-body irradiation and chemotherapy. GVHD prophylaxis was with tacrolimus, with or without methotrexate or mycophenolate mofetil. Subjects received CD34-selected PBSC and a defined dose of memory T cells depleted of T. Median follow-up was 4 years. The primary outcome of the analysis of cumulative data from the three trials was cGVHD.

RESULTS

cGVHD was very infrequent and mild (3-year cumulative incidence total, 7% [95% CI, 2 to 11]; moderate, 1% [95% CI, 0 to 2]; severe, 0%). Grade III and IV acute GVHD (aGVHD) occurred in 4% (95% CI, 1 to 8) and 0%, respectively. The cumulative incidence of grade II aGVHD, which was mostly stage 1 upper gastrointestinal GVHD, was 71% (95% CI, 64 to 79). Recipients of matched related donor and matched unrelated donor grafts had similar rates of grade III aGVHD (5% [95% CI, 0 to 9] and 4% [95% CI, 0 to 9]) and cGVHD (7% [95% CI, 2 to 13] and 6% [95% CI, 0 to 12]). Overall survival, cGVHD-free, relapse-free survival, relapse, and nonrelapse mortality were, respectively, 77% (95% CI, 71 to 85), 68% (95% CI, 61 to 76), 23% (95% CI, 16 to 30), and 8% (95% CI, 3 to 13) at 3 years.

CONCLUSION

Depletion of T from PBSC allografts results in very low incidences of severe acute and any cGVHD, without apparent excess risks of relapse or nonrelapse mortality, distinguishing this novel graft engineering strategy from other hematopoietic cell transplantation approaches.

摘要

目的

移植物抗宿主病(GVHD)会导致异基因造血细胞移植后发病率和死亡率升高。幼稚 T 细胞(T 细胞)在小鼠模型中会引发严重的 GVHD。我们评估了外周血干细胞(PBSC)移植物 T 细胞耗竭的三项 II 期临床试验中的慢性 GVHD(cGVHD)和其他结局。

方法

138 例急性白血病患者在高剂量或中剂量全身照射和化疗预处理后,接受 HLA 匹配的亲缘或无关供体的 T 细胞耗竭 PBSC。GVHD 预防采用他克莫司,联合或不联合甲氨蝶呤或霉酚酸酯。患者接受 CD34 选择的 PBSC 和定义剂量的 T 细胞耗竭的记忆 T 细胞。中位随访时间为 4 年。对三项试验累积数据的分析的主要结局是 cGVHD。

结果

cGVHD 非常罕见且轻微(3 年累积发生率总,7%[95%CI,2 至 11%];中度,1%[95%CI,0 至 2%];重度,0%)。3 级和 4 级急性 GVHD(aGVHD)分别为 4%(95%CI,1 至 8)和 0%。2 级 aGVHD 的累积发生率很高(95%CI,64%至 79%),主要为 1 期上消化道 GVHD。匹配亲缘供体和匹配无关供体移植物受者的 3 级 aGVHD 发生率相似(5%[95%CI,0 至 9]和 4%[95%CI,0 至 9])和 cGVHD(7%[95%CI,2 至 13]和 6%[95%CI,0 至 12])。3 年时,总生存、无 cGVHD 生存、无复发生存、复发和非复发死亡率分别为 77%(95%CI,71%至 85%)、68%(95%CI,61%至 76%)、23%(95%CI,16%至 30%)和 8%(95%CI,3%至 13%)。

结论

从 PBSC 同种异体移植物中耗竭 T 细胞可导致严重急性和任何 cGVHD 的发生率非常低,而复发或非复发死亡率没有明显增加,这使这种新型移植物工程策略有别于其他造血细胞移植方法。

相似文献

1
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.
J Clin Oncol. 2022 Apr 10;40(11):1174-1185. doi: 10.1200/JCO.21.01755. Epub 2022 Jan 10.
3
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
J Clin Invest. 2015 Jul 1;125(7):2677-89. doi: 10.1172/JCI81229. Epub 2015 Jun 8.
7
Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Transplant Cell Ther. 2023 Sep;29(9):575.e1-575.e6. doi: 10.1016/j.jtct.2023.05.022. Epub 2023 Jun 9.
9
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Sep;25(9):1875-1883. doi: 10.1016/j.bbmt.2019.05.007. Epub 2019 May 11.
10
High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Transplant Cell Ther. 2021 Jul;27(7):619.e1-619.e8. doi: 10.1016/j.jtct.2021.03.022. Epub 2021 Mar 25.

引用本文的文献

1
Graft Source Choice.
Adv Exp Med Biol. 2025;1475:57-75. doi: 10.1007/978-3-031-84988-6_4.
2
NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update.
Transplant Cell Ther. 2025 May 21. doi: 10.1016/j.jtct.2025.05.016.
3
A donor PD-1CD8 T-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease.
Signal Transduct Target Ther. 2025 Apr 2;10(1):120. doi: 10.1038/s41392-025-02183-1.
5
Cellular therapies for the prevention and treatment of acute graft-versus-host disease.
Stem Cells. 2025 May 27;43(6). doi: 10.1093/stmcls/sxaf009.
6
Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.
Methods Mol Biol. 2025;2907:1-56. doi: 10.1007/978-1-0716-4430-0_1.
7
"Attack!" Cellular Therapies to Attack Pathogens and Tumors.
Transfus Med Hemother. 2025 Feb 4;52(1):1-4. doi: 10.1159/000543415. eCollection 2025 Feb.
8
Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future.
Transplantation. 2025 Feb 7. doi: 10.1097/TP.0000000000005345.

本文引用的文献

2
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
J Clin Oncol. 2021 Jun 10;39(17):1865-1877. doi: 10.1200/JCO.20.01086. Epub 2021 Jan 15.
3
Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
N Engl J Med. 2021 Jan 7;384(1):11-19. doi: 10.1056/NEJMoa2027372.
4
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
J Clin Oncol. 2020 Apr 20;38(12):1273-1283. doi: 10.1200/JCO.19.03011. Epub 2019 Dec 20.
5
Disability Related to Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2020 Apr;26(4):772-777. doi: 10.1016/j.bbmt.2019.10.019. Epub 2019 Oct 24.
6
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Nat Med. 2019 Jul;25(7):1064-1072. doi: 10.1038/s41591-019-0472-9. Epub 2019 Jun 24.
7
Donor Allospecific CD44 Central Memory T Cells Have Decreased Ability to Mediate Graft-vs.-Host Disease.
Front Immunol. 2019 Apr 2;10:624. doi: 10.3389/fimmu.2019.00624. eCollection 2019.
8
Posttransplant chimeric antigen receptor therapy.
Blood. 2018 Mar 8;131(10):1045-1052. doi: 10.1182/blood-2017-08-752121. Epub 2018 Jan 22.
9
Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.
Blood. 2018 Jan 4;131(1):108-120. doi: 10.1182/blood-2017-07-791608. Epub 2017 Oct 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验